How do we optimize outcomes for patients with severe community-acquired pneumonia?

Intensive Care Medicine

Volumn 28, Issue 8, 2002, Pages 1003-1005

  Niederman, Michael S ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MORTALITY; PNEUMONIA; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0036360709     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1324-4     Document Type: Editorial

References (12)

1. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU
2. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia
3. Guidelines for the management of adults with community-acquired lower respiratory tract infections: Diagnosis, assessment of severity, antimicrobial therapy and prevention
4. Etiology of community-acquired pneumonia: Impact of age, comorbidity, and severity
5. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
6. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states: 1993, 1995, 1997
7. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia
8. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia
9. Practice guidelines for the management of community-acquired pneumonia in adults
10. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae therapeutic working group
11. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
12. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia